Boston Scientific Corporation (NYSE: BSX) delivered exceptional first-quarter 2024 results, fueled by the strength of its diversified businesses and a robust pipeline. Net sales reached , reflecting a 13.8% increase on a reported basis, a 15.0% increase on an operational basis, and a 13.1% increase on an organic basis compared to the same period last year.
The company reported a GAAP net income attributable to Boston Scientific common stockholders of , or per share (EPS), compared to or per share a year ago. Notably, adjusted EPS for the period reached , surpassing last year’s figure.
Boston Scientific’s chairman and CEO, , attributed the impressive results to the company’s talented global team and the strength of its diversified businesses and pipeline, particularly highlighting the initial U.S. launch of the FARAPULSE™ Pulsed Field Ablation System. He emphasized the company’s ongoing commitment to long-term investment in innovation and clinical science to benefit patients worldwide while delivering exceptional financial performance.
For the full year 2024, the company estimates net sales growth of approximately 11 to 13 percent on a reported basis and 10 to 12 percent on an organic basis. Organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures with less than a full period of comparable net sales. EPS on a GAAP basis is estimated in the range of to , while adjusted EPS, excluding certain charges (credits), is projected to be in the range of to .
In the second quarter of 2024, Boston Scientific anticipates net sales growth of approximately 10.5 to 12.5 percent on a reported basis and approximately 10 to 12 percent on an organic basis. Organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures with less than a full period of comparable net sales. EPS on a GAAP basis is estimated to be in the range of to , and adjusted EPS, excluding certain charges (credits), is projected to be in the range of to .
Boston Scientific’s management will discuss these results with analysts on a conference call today at . The company will webcast the call to interested parties through its website: . For details on accessing the webcast, please visit the website. The webcast will be available for approximately one year on the Boston Scientific website.
